Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Larimar's Nomlabofusp Shows Promise for Friedreich's Ataxia, Despite Safety Concerns

Larimar's Nomlabofusp Shows Promise for Friedreich's Ataxia, Despite Safety Concerns

Larimar Therapeutics has reported significant improvements in functional outcomes for patients with Friedreich's ataxia (FA) treated with its investigational frataxin therapy, nomlabofusp. However, safety concerns have dampened investor enthusiasm, leading to a 33% drop in the company's stock price.

NoahAI News10/1/2025
Fractyl Health's Revita System Shows Promise in Maintaining GLP-1 Weight Loss

Fractyl Health's Revita System Shows Promise in Maintaining GLP-1 Weight Loss

Fractyl Health has reported encouraging midpoint data from its REMAIN-1 study, demonstrating that its Revita system can help maintain or even continue weight loss in patients who discontinue GLP-1 medication. This development marks a significant milestone in the company's pivot from diabetes treatment to addressing the growing obesity market.

NoahAI News10/1/2025
Metsera's Obesity Drug Shows Promise, Strengthening Pfizer's $4.9 Billion Acquisition

Metsera's Obesity Drug Shows Promise, Strengthening Pfizer's $4.9 Billion Acquisition

Metsera's experimental obesity drug MET-097i has demonstrated significant weight loss results in a Phase 2 trial, bolstering Pfizer's recent decision to acquire the company for $4.9 billion. The study outcomes, announced Monday, reveal a weight reduction profile comparable to Eli Lilly's Zepbound, positioning Pfizer to potentially compete in the rapidly expanding obesity treatment market.

NoahAI News10/1/2025
FDA Official's LinkedIn Post Sparks Controversy Over Surrogate Endpoints and Lupus Drug

FDA Official's LinkedIn Post Sparks Controversy Over Surrogate Endpoints and Lupus Drug

In a surprising turn of events, the pharmaceutical industry has been buzzing with controversy following a now-deleted LinkedIn post by Dr. George Tidmarsh, director of the FDA's Center for Drug Evaluation and Research (CDER). The post, which targeted the use of surrogate endpoints in drug approvals and specifically called out Aurinia Pharmaceuticals' lupus nephritis drug Lupkynis, has raised questions about the FDA's stance on approval processes and the future of certain approved medications.

NoahAI News10/1/2025
South Korean Boryung Acquires Sanofi's Taxotere Rights in $205M Deal

South Korean Boryung Acquires Sanofi's Taxotere Rights in $205M Deal

South Korea-based Boryung Corporation has struck a significant deal with French pharmaceutical giant Sanofi, acquiring the rights to the chemotherapy drug Taxotere (docetaxel) in 19 markets for up to €175 million ($205 million). This strategic move aims to bolster Boryung's global oncology presence and address supply chain challenges for the essential cancer treatment.

NoahAI News10/1/2025
Yale New Haven Exits Hospital Acquisition Deal, Prospect Medical Seeks New Buyers

Yale New Haven Exits Hospital Acquisition Deal, Prospect Medical Seeks New Buyers

Yale New Haven Health has reached an agreement to pay Prospect Medical Holdings $45 million to terminate a previous deal to acquire three Connecticut hospitals. This development comes amid Prospect's bankruptcy proceedings and ongoing efforts to sell its assets, including the hospitals in question.

NoahAI News10/1/2025
Olympus Launches AI-Powered Polyp Detection System for Colonoscopies

Olympus Launches AI-Powered Polyp Detection System for Colonoscopies

Olympus, a leading medical technology company, has unveiled its first artificial intelligence (AI) application for the U.S. market, marking a significant advancement in gastrointestinal (GI) endoscopy. The new AI-powered system, called Caddie, is designed to assist clinicians in detecting polyps during colonoscopies, potentially improving early diagnosis rates for colorectal cancer.

NoahAI News10/1/2025
AnaptysBio to Split into Two Companies, Separating Biotech Pipeline from Royalty Assets

AnaptysBio to Split into Two Companies, Separating Biotech Pipeline from Royalty Assets

AnaptysBio, a San Diego-based biopharmaceutical company, has announced plans to split into two separate publicly traded entities. This strategic move aims to create distinct businesses focused on clinical-stage pipeline development and royalty-based agreements, respectively.

NoahAI News10/1/2025
Novartis Scores FDA Approval for Rhapsido in Chronic Hives, Intensifying BTK Inhibitor Competition

Novartis Scores FDA Approval for Rhapsido in Chronic Hives, Intensifying BTK Inhibitor Competition

Novartis has secured FDA approval for Rhapsido (remibrutinib), an oral BTK inhibitor for the treatment of chronic spontaneous urticaria (CSU), commonly known as chronic hives. This approval marks a significant milestone in the pharmaceutical industry, potentially reshaping the landscape of immunology treatments and setting the stage for heightened competition in the BTK inhibitor market.

NoahAI News10/1/2025
Northwell Health's New CEO Outlines Strategy Amid Healthcare Challenges

Northwell Health's New CEO Outlines Strategy Amid Healthcare Challenges

John D'Angelo, M.D., the newly appointed CEO of Northwell Health, has unveiled his vision for navigating the complex healthcare landscape, emphasizing growth, technology adoption, and community engagement. As he steps into the role following Michael Dowling's tenure, D'Angelo faces a healthcare industry grappling with financial pressures and evolving patient needs.

NoahAI News10/1/2025
Millie Expands Women's Health Services to Include Perimenopause and Menopause Care

Millie Expands Women's Health Services to Include Perimenopause and Menopause Care

Millie, a California-based hybrid women's health clinic, has announced the expansion of its services to include perimenopause and menopause care. This move broadens the company's focus beyond its initial maternity care offerings, addressing a growing need in women's healthcare.

NoahAI News10/1/2025
Novo Nordisk Terminates $598M Cell Therapy Collaboration with Heartseed Amid Strategic Restructuring

Novo Nordisk Terminates $598M Cell Therapy Collaboration with Heartseed Amid Strategic Restructuring

Danish pharmaceutical giant Novo Nordisk has ended its collaboration with Japanese biotech Heartseed, scrapping a potential $598 million deal focused on developing an allogeneic cell therapy for advanced heart failure. The termination comes as part of Novo's company-wide restructuring efforts, which aim to concentrate resources on diabetes and obesity treatments.

NoahAI News10/1/2025
«1...404142...67»